AMACR/p504s Recombinant Rabbit mAb (Alexa Fluor??555 Conjugate) (SDT-401-29)

產(chǎn)品型號：S0B1573

更新時間：2025-10-10

廠商性質(zhì)：生產(chǎn)廠家

訪問量：90

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

如何選擇合適的偶聯(lián)抗體用于實驗研究？

熒光偶聯(lián)抗體：如何在生物醫(yī)學研究中實現(xiàn)精準檢測？

視黃醇結(jié)合蛋白4（RBP4）抗體：發(fā)掘其在疾病風險中的診斷潛力

腫瘤靶點的“新寵”-Claudin18.2抗體現(xiàn)貨！

產(chǎn)品介紹

α-Methylacyl-CoA racemase （AMACR; P504S） catalyzes a key chiral inversion step in the metabolism of branched-chain fatty acids, ibuprofen and related drugs. Protein levels are increased in all prostate and some other cancer cells and it is used as a marker （P504S）. The enzyme requires no cofactors and catalyzes its reaction by a stepwise 1,1-proton transfer via an enolate intermediate. The biological role of AMACR in cancer is complex, linking lipid metabolism with nuclear receptor （e.g. FXR and PPAR） activity and expression of enzymes such as cyclooxygenase-2 （COX-2）. A number of rationally designed AMACR inhibitors have been reported in the literature as potential cancer treatments. The opportunities and challenges for development of acyl-CoA esters as inhibitors are discussed from a medicinal chemical viewpoint. Other challenges for drug development include the problems in assaying enzymatic activity and the prediction of structure-activity relationships （SAR）. [PMID: 23376124]

上一個：S0B1574CA125 Recombinant Rabbit mAb (Alexa Fluor??555 Conjugate) (SDT-555-41)